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(First published online 23 June 2008)
Randomisation of participants in two study groups leads to
groups that have baseline differences accountable by the play
of chance. In small trials, the random variation between two
study groups can be large, but in large studies the variation
is typically small.
When we compare the Alpha-Tocopherol Beta-Carotene
Cancer Prevention (ATBC) Study participants with high dietary
vitamin C intake(1) administered vitamin E (n 6734) with those
not administered vitamin E (n 6768), the average BMI and age
are equal within 1 % accuracy: 26·43 v. 26·50 kg/m2 and 57·35
v. 57·30 years, respectively. Previously, we reported that being
widowed, living in a village or the countryside, and smoking $
twenty-six cigarettes per d at the baseline were associated with a
significantly higher risk of tuberculosis(2). Among the partici-
pants with a high vitamin C intake, the distribution of these
characteristics is also balanced with great accuracy in the vita-
min E and no-vitamin E groups: 187 v. 187, 2296 v. 2397, and
1181 v. 1092 participants, respectively.
To propose that the 72 % higher incidence of tuberculosis
in the vitamin E-supplemented participants might be explained
by the maldistribution of a strong risk factor requires that the
risk factor should be over 72 % more prevalent in the vitamin
E-supplemented group. Given the closely equal distribution of
the five risk factors described above, there is no justification to
assume that any other risk factor would be unbalanced to such
a degree that it could explain the 72 % difference between the
two groups.
Finally, the initiation of vitamin E supplementation provides
a reasonable explanation for the rapid increase in tuberculosis
incidence after randomisation in the heavy smokers with high
vitamin C intake (see Fig. 1 of Hemilä & Kaprio(1)). Such a
sudden effect of brief duration cannot be explained by a risk
factor that is permanent or long lasting before randomisation.
In our study(1), we referred to the original ATBC Study
reports for a detailed description of the design and methods.
Potential participants were excluded from the study, for
example, for proven malignancy other than non-melanoma
skin cancer or carcinoma in situ, chronic renal insufficiency,
cirrhosis of the liver, chronic alcoholism, or medical
problems that might limit participation for 6 years(3). How-
ever, the exclusion or inclusion of such participants is not
related to the validity of the vitamin E supplementation anal-
ysis, because, if included, they would have been equally
divided between the intervention groups. In our study(1), we
excluded active tuberculosis cases that occurred before
randomisation. We described that most probably the majority
of our participants had latent tuberculosis infection from their
youth. However, this does not mean misclassification. Most
individuals with latent tuberculosis infection live their lives
without getting active tuberculosis; for example, globally
about 2000 million individuals have latent tuberculosis infec-
tion, but only 8 million new cases of active tuberculosis occur
annually(4). If vitamin E supplementation increases the risk of
activation of latent tuberculosis in certain population groups,
as our study suggests, vitamin E supplementation should be
discouraged in particular in developing countries in which
latent tuberculosis is prevalent.
A particular strength of large randomised trials is that
potential risk factors need not be assessed at the baseline
because they are distributed close to equally between the
study groups. No great increase in statistical sensitivity is
likely to be conferred by stratification and/or adjustment for
prognostic features in large trials(5). It has even been argued
that ‘collecting less information may mean bigger numbers
and hence better science: many trials still collect ten or a
hundred times too much information per patient (which)
may, paradoxically, substantially reduce the reliability with
which therapeutic questions are answered, if their indirect
effect is to make randomised trials smaller’(6).
In our study, the interaction between vitamin E supplemen-
tation and dietary vitamin C intake was statistically significant
(P¼0·042), which justified the examination of the vitamin C
subgroups separately(1). Nevertheless, even if all the ATBC
Study participants (n 29 023) are examined together, the lower
limit of the CI for the vitamin E effect on tuberculosis risk
(213 to þ59 %), and the lack of interaction with age(1), refutes
the proposal that vitamin E supplementation would lead to gen-
eralised benefits on the immune system in elderly individuals(7).
We declare no conflict of interest.
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